Rapport Therapeutics (RAPP) Competitors $28.03 -3.44 (-10.93%) Closing price 04:00 PM EasternExtended Trading$27.90 -0.13 (-0.46%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RAPP vs. IMVT, CPRX, KNSA, TARS, OGN, ALVO, CNTA, DNLI, IBRX, and AGIOShould you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include Immunovant (IMVT), Catalyst Pharmaceuticals (CPRX), Kiniksa Pharmaceuticals International (KNSA), Tarsus Pharmaceuticals (TARS), Organon & Co. (OGN), Alvotech (ALVO), Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), ImmunityBio (IBRX), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry. Rapport Therapeutics vs. Its Competitors Immunovant Catalyst Pharmaceuticals Kiniksa Pharmaceuticals International Tarsus Pharmaceuticals Organon & Co. Alvotech Centessa Pharmaceuticals Denali Therapeutics ImmunityBio Agios Pharmaceuticals Rapport Therapeutics (NASDAQ:RAPP) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk. Do analysts recommend RAPP or IMVT? Rapport Therapeutics presently has a consensus target price of $31.00, suggesting a potential upside of 10.60%. Immunovant has a consensus target price of $33.60, suggesting a potential upside of 104.88%. Given Immunovant's higher probable upside, analysts clearly believe Immunovant is more favorable than Rapport Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Immunovant 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83 Is RAPP or IMVT more profitable? Rapport Therapeutics' return on equity of -29.99% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets Rapport TherapeuticsN/A -29.99% -28.64% Immunovant N/A -80.99%-72.23% Does the media refer more to RAPP or IMVT? In the previous week, Immunovant had 1 more articles in the media than Rapport Therapeutics. MarketBeat recorded 18 mentions for Immunovant and 17 mentions for Rapport Therapeutics. Immunovant's average media sentiment score of 1.08 beat Rapport Therapeutics' score of 0.77 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 10 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, RAPP or IMVT? Rapport Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Which has higher valuation and earnings, RAPP or IMVT? Rapport Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapport TherapeuticsN/AN/A-$78.31M-$2.50-11.21ImmunovantN/AN/A-$413.84M-$2.85-5.75 Do insiders and institutionals hold more shares of RAPP or IMVT? 47.1% of Immunovant shares are held by institutional investors. 13.6% of Rapport Therapeutics shares are held by insiders. Comparatively, 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryRapport Therapeutics and Immunovant tied by winning 7 of the 14 factors compared between the two stocks. Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPP vs. The Competition Export to ExcelMetricRapport TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02B$3.14B$5.81B$10.03BDividend YieldN/A2.27%6.67%4.54%P/E Ratio-11.2121.4875.7526.29Price / SalesN/A233.25449.5181.86Price / CashN/A44.1225.7029.20Price / Book3.3610.0511.506.43Net Income-$78.31M-$53.33M$3.28B$270.56M7 Day Performance71.23%2.18%1.30%3.01%1 Month Performance92.65%11.91%11.25%9.74%1 Year Performance42.57%14.14%59.54%26.68% Rapport Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPPRapport Therapeutics1.5758 of 5 stars$28.03-10.9%$31.00+10.6%+54.8%$1.02BN/A-11.21N/ATrending NewsAnalyst ForecastOptions VolumeHigh Trading VolumeIMVTImmunovant2.504 of 5 stars$14.69-0.9%$35.20+139.6%-51.9%$2.56BN/A-5.15120Positive NewsCPRXCatalyst Pharmaceuticals4.9103 of 5 stars$20.59+1.0%$33.20+61.2%+2.4%$2.52B$491.73M12.4880Positive NewsKNSAKiniksa Pharmaceuticals International3.2054 of 5 stars$33.490.0%$41.17+22.9%+46.7%$2.48B$423.24M837.46220News CoverageAnalyst UpgradeInsider TradeTARSTarsus Pharmaceuticals2.244 of 5 stars$58.58+0.7%$66.67+13.8%+86.0%$2.47B$182.95M-25.1450Positive NewsOGNOrganon & Co.4.6514 of 5 stars$9.40+2.3%$18.00+91.6%-48.9%$2.45B$6.40B3.494,000News CoveragePositive NewsALVOAlvotech3.0735 of 5 stars$8.07+0.2%$14.00+73.5%-26.4%$2.43B$491.98M35.091,032Short Interest ↑CNTACentessa Pharmaceuticals3.2904 of 5 stars$16.79+1.4%$31.50+87.6%+26.1%$2.25B$6.85M-9.38200Positive NewsDNLIDenali Therapeutics4.3818 of 5 stars$15.27-2.4%$33.62+120.1%-38.6%$2.23B$330.53M-5.45430News CoveragePositive NewsAnalyst ForecastIBRXImmunityBio2.7137 of 5 stars$2.34+0.4%$10.75+359.4%-28.7%$2.21B$14.74M-4.87590Analyst ForecastAGIOAgios Pharmaceuticals4.2812 of 5 stars$37.71-1.2%$56.33+49.4%-15.9%$2.19B$36.50M3.43390News CoverageInsider TradeAnalyst Revision Related Companies and Tools Related Companies IMVT Competitors CPRX Competitors KNSA Competitors TARS Competitors OGN Competitors ALVO Competitors CNTA Competitors DNLI Competitors IBRX Competitors AGIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPP) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
